AEON Biopharma, Inc. (AEON) Income Statement
AEON 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAEON revenue and net income
AEON profit margins
AEON growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | −117.5% | — | — | — |
| Net income | −193.4% | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AEON quarterly EPS vs estimates
AEON Biopharma beat the analyst EPS estimate in 4 of the last 6 quarters. Next report: November 13, 2026 (estimate $-0.10).
AEON income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $2.5M | $3.4M |
| Cost of revenue | $78,000 | — | — | — | — | $0 | $1,000 |
| Gross profit | −$78,000 | — | — | — | — | $2.5M | $3.4M |
| Research & development | $4.1M | $14.2M | $33.0M | $34.8M | $25.7M | $7.3M | $4.8M |
| Sales, general & admin | $12.2M | $13.6M | — | $13.7M | $11.2M | $11.6M | $46.0M |
| Total operating expenses | $12.8M | −$73.0M | $348.1M | $48.4M | $65.8M | $18.9M | $57.3M |
| Operating income | −$12.8M | $73.0M | −$348.1M | −$48.4M | −$65.8M | −$16.4M | −$54.0M |
| Interest income | — | — | — | — | — | $0 | $720,000 |
| Interest expense | — | — | — | — | — | $15,000 | $7.5M |
| Income before taxes | −$39.2M | $42.0M | −$384.6M | −$52.6M | −$55.6M | −$32.9M | $145.7M |
| Income taxes | — | — | — | −$160,485 | $29.0M | $15,000 | $14.6M |
| Net income | −$39.2M | $42.0M | −$384.6M | −$52.6M | −$55.6M | −$32.9M | $172.9M |
| EBITDA | −$16.2M | −$27.7M | −$52.7M | −$52.5M | −$36.9M | −$15.5M | −$47.5M |
| EPS (diluted) | −$2.43 | −$2.99 | −$1.60 | $13.31 | −$9.54 | — | — |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% |
| Operating margin | — | — | — | — | — | −650.8% | −1,607.6% |
| Net margin | — | — | — | — | — | −1,307.1% | 5,151.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $20,000 | $19,000 | $20,000 | — | — | — | — | — | — | — | — | — |
| Gross profit | −$20,000 | −$19,000 | −$20,000 | — | — | — | — | — | — | — | — | — |
| Research & development | $2.9M | $2.0M | $1.6M | $597,000 | $1.1M | $825,000 | $3.0M | $972,000 | $4.4M | $5.7M | $6.9M | $8.0M |
| Sales, general & admin | $3.0M | $3.9M | $3.9M | $1.9M | $3.3M | $3.1M | $2.6M | $3.0M | $3.3M | $4.6M | — | — |
| Total operating expenses | $5.9M | $5.9M | $5.5M | $2.5M | $4.3M | $462,000 | $2.3M | $4.0M | −$153.5M | $74.2M | $34.7M | $286.3M |
| Operating income | −$5.9M | −$5.9M | −$5.5M | −$2.5M | −$4.3M | −$462,000 | −$2.3M | −$4.0M | $153.5M | −$74.2M | −$34.7M | −$286.3M |
| Income before taxes | −$1.2M | −$11.8M | −$37.1M | −$4.5M | −$6.6M | $9.1M | $2.1M | −$6.2M | $164.1M | −$118.0M | −$26.2M | −$325.4M |
| Income taxes | — | — | — | — | — | — | — | — | −$170.0M | $107.6M | — | — |
| Net income | −$1.2M | −$11.8M | −$37.1M | −$4.5M | −$6.6M | $9.1M | $2.1M | −$6.2M | $164.1M | −$118.0M | −$26.2M | −$325.4M |
| EBITDA | −$5.9M | −$11.8M | −$5.5M | −$2.5M | −$4.3M | −$3.9M | −$5.6M | −$6.1M | −$7.7M | −$10.4M | −$11.5M | −$14.3M |
| EPS (diluted) | −$0.02 | −$0.25 | −$3.72 | −$0.39 | −$0.60 | $2.28 | $3.47 | −$11.52 | $5.34 | −$0.28 | −$51.12 | $82.80 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AEON's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AEON financial results
AEON Biopharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $39.2 million. Diluted earnings per share came to −$2.43.
See the AEON stock overview for the latest quote and news, or the AEON chart for price history and technical indicators.
AEON income statement FAQ
Does AEON Biopharma have revenue?
AEON Biopharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is AEON Biopharma profitable?
No. AEON Biopharma reported a net loss of $39.2 million in fiscal 2025.
How much does AEON Biopharma spend on research and development?
AEON Biopharma spent $4.1 million on research and development in fiscal 2025.
What are AEON Biopharma's earnings per share?
AEON Biopharma earned $-2.43 per diluted share in fiscal 2025, compared with $-2.99 a year earlier.
When will AEON Biopharma report its next earnings?
AEON Biopharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does AEON Biopharma's fiscal year end?
AEON Biopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.